Selective Evolution of Stromal Mesenchyme with p53 Loss in Response to Epithelial Tumorigenesis  by Hill, Reginald et al.
Selective Evolution of Stromal
Mesenchyme with p53 Loss
in Response to Epithelial Tumorigenesis
Reginald Hill,1 Yurong Song,2 Robert D. Cardiff,3 and Terry Van Dyke2,*
1Curriculum in Genetics and Molecular Biology
2Department of Genetics
University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
3Center for Comparative Medicine, University of California at Davis, Davis, CA 95616, USA
*Contact: tvdlab@med.unc.edu
DOI 10.1016/j.cell.2005.09.030SUMMARY
Our understanding of cancer has largely
come from the analysis of aberrationswithin
the tumor cell population. Yet it is increas-
ingly clear that the tumor microenvironment
can significantly influence tumorigenesis.
For example, the mesenchyme can support
the growth of tumorigenic epithelium. How-
ever, whether fibroblasts are subject to
genetic/epigenetic changesasa result of se-
lective pressures conferred by oncogenic
stress in the epithelium has not been ex-
perimentally assessed. Recent analyses of
some human carcinomas have shown tu-
mor-suppressor gene mutations within the
stroma, suggesting that the interplay among
multiple cell types can select for aberrations
nonautonomously during tumor progres-
sion. We demonstrate that this indeed oc-
curs in a mouse model of prostate cancer
where epithelial cell cycle disruption via
cell-specific inhibition of pRb function indu-
ces a paracrine p53 response that sup-
pressesfibroblastproliferation inassociated
stroma. This interaction imposes strong se-
lective pressure yielding a highly prolifera-
tive mesenchyme that has undergone p53
loss.
INTRODUCTION
Epithelial-mesenchymal interactions are critical in regulating
many aspects of vertebrate embryo development, and stud-
ies have shown that input from the stroma is necessary not
only for the development of many structures including theCellprostate (Cunha et al., 1996; Podlasek et al., 1999), mam-
mary gland (Sakakura, 1991), and limb (Johnson and Tabin,
1997) but also for the maintenance of homeostatic equilib-
rium in adult tissueswith the stromal cells maintaining control
over cell size, function, and response to wounds and other
pathological conditions (reviewed in Tlsty and Hein [2001])
through modification of the extracellular matrix (ECM). Re-
cently, the uterine stroma has been shown to mediate
both developmental and estrogen-mediated changes in
the epithelium, a process involving Wnt5a (Mericskay et al.,
2004). The interactions between epithelium and mesen-
chyme are believed to be mediated by paracrine signals
and ECM components secreted from developing mesen-
chyme that affect adjacent epithelia (Cunha et al., 1980). In
response to tumorigenesis in adjacent epithelial cells, fibro-
blasts, a major stromal component, also undergo changes
that may alter the normal epithelial-mesenchymal interac-
tions (Bergers and Coussens, 2000). Several experimental
systems have further shown that such ‘‘cancer-associated’’
fibroblasts can enhance the tumorigenic properties of the
epithelial compartment (Barcellos-Hoff and Ravani, 2000;
Bhowmick et al., 2004b; Cunha et al., 2003; Ohuchida
et al., 2004). However, whether the tumor mesenchyme
undergoes selective genetic or epigenetic changes in spe-
cific loci in response to epithelial tumorigenesis and thus
can coevolve has not been experimentally examined.
Recently, several labs have reported the mutation of the
tumor-suppressor genes, including p53, in the stromal com-
partment of human carcinomas. p53 is mutated in the most
advanced forms of human cancers, comprising most tumor
types (Levine et al., 1991; Nigro et al., 1989; Hollstein et al.,
1991). In response to several stress signals, including onco-
gene activation, DNA damage, and physiological stress, p53
levels increase leading either to growth arrest or apoptosis
(reviewed in Harris and Levine [2005]; Vousden and Lu,
2002). Because of its checkpoint roles, p53 inactivation
can also contribute to tumorigenesis by propagation of ge-
nomic instability. The stimulation of angiogenesis has also
been associated with p53 loss (Dameron et al., 1994; Yu
et al., 1997). The factors that determine which response is
elicited are not clearly understood, although cell type and123, 1001–1011, December 16, 2005 ª2005 Elsevier Inc. 1001
nature of the stress appear to have a role. Yet recent evi-
dence showing p53 alterations in the stroma associated
with carcinomas of many tissue types (Fukino et al., 2004;
Kurose et al., 2001, 2002; Matsumoto et al., 2003; Moinfar
et al., 2000; Paterson et al., 2003; Tuhkanen et al., 2004;
Wernert et al., 2001), including the prostate (see Discussion),
suggests non-cell-autonomous mechanisms for p53 induc-
tion could play a role in tumor suppression. Although onco-
genic stress (the induction of tumorigeneic properties) has
previously been shown to cell-autonomously induce p53 re-
sponses (Vousden, 2002), leading to selective pressure for
p53 inactivation and tumor progression, whether cell nonau-
tonomous induction of p53may play a role in tumor evolution
has not been explored.
Here, we uncover such a mechanism in the study of a ge-
netically engineered spontaneous prostate cancer model.
TgAPT121 mice develop extensive prostatic intraepithelial
neoplasia (mPIN) as a result of inactivating pRb and related
proteins p107 and p130 specifically in prostate epithelium
by probasin-driven expression of T121 (a 121 aa N-terminal
fragment of SV40 large T antigen). T121 fully inactivates
pRb function by eliminating the redundancy/compensation
provided by p107 and/or p130 commonly observed in the
mouse (Dannenberg et al., 2000; Lee et al., 1996; Luo
et al., 1998; Robanus-Maandag et al., 1998; Sage et al.,
2000; Xiao et al., 2002). We previously showed that T121-
induced mPIN results from extensive aberrant epithelial pro-
liferation accompanied by Pten-dependent apoptosis. By
4 months, mPIN lesions progress to microinvasive adeno-
carcinoma in all animals, a process that is accelerated in
a Pten+/ background (Hill et al., 2005). In an effort to deter-
mine the role, if any, for p53 in prostate cancer suppression,
we examined the development of prostate lesions in
TgAPT121mice with alterations in the p53 genotype. Surpris-
ingly, while epithelial apoptosis and proliferation is unaf-
fected by p53 deficiency (Hill et al., 2005), a significant role
for p53 in themesenchymewas induced by the T121-initiated
epithelium. Here, we examine the impact of this paracrine-
selective pressure on tumor evolution.
RESULTS
Increased Mesenchymal Response in TgAPT121
Prostate upon p53 Deficiency
We assessed the role of p53 in prostate tumor suppression
by examining the progression of tumors in TgAPT121 mice
that were wild-type, heterozygous, or null for p53. Prostates
of wild-type mice consist of normal glandular architecture
with a single luminal epithelial cell layer (Figure 1A, arrow)
and an underlying basal cell layer separated from surround-
ing stroma (Figure 1A, arrowhead) by a basementmembrane
(Shappell et al., 2004; Figure 1A). As previously reported (Hill
et al., 2005), TgAPT121;p53
+/+ prostates, in which T121 is in-
duced in the epithelium upon androgen induction at puberty,
are extensively dysplastic by 2 months of age, with the epi-
thelium characterized by nuclear atypia and loss of single-
layer architecture (Figure 1B). In these mice, disease
progression is reproducible and 100% penetrant, with wide-
spread dysplasia becoming murine prostatic intraductal1002 Cell 123, 1001–1011, December 16, 2005 ª2005 Elsevier Inneoplasia (mPIN) and producing minimally invasive adeno-
carcinoma over time (Figure 1J; Hill et al., 2005). At early
times (<3 months), TgAPT121;p53
+/ prostates were indis-
tinguishable from those of TgAPT121;p53
+/+ littermates (Fig-
ures 1C and 1K), while the TgAPT121;p53
/ prostate epi-
thelium was morphologically distinguishable in that nuclear
atypia, including multinucleation, was more extensive with
earlier onset (Figures 1D and 1L). Notably, subsequent to
T121 expression in the epithelial compartment, p53-deficient
TgAPT121 prostates contained an extensive hypercellular
mesenchyme (Figure 1E, star), consistent with a strong stro-
mal response upon p53 inactivation in one or more compart-
ments. Importantly, p53/ prostates are morphologically
normal (not shown). Thus, these effects, including the mes-
enchymal response, are dependent on expression of the
T121 exclusively in the epithelium (Figure 1I; Hill et al., 2005).
Tumor Progression with Massive Stromal
Involvement Facilitated in p53 Heterozygous
and Null TgAPT121 Mice
Further evidence for a stromal p53 effect came from the
analysis of tumor progression. In TgAPT121;p53
+/ mice,
distinct tumors emerged focally from the anterior prostate
at 5 months of age (Figure 1F, arrows, and Figure 1K) and
grew rapidly, becoming massive by about 7 months (Fig-
ure 1K). In addition to the adenocarcinoma histopathology
observed in TgAPT121;p53
+/+ prostates (Figure 1J; Hill
et al., 2005), these tumors had developed an extensive ab-
normal mesenchyme (Figure 1G, star), which expressed fi-
broblast markers smooth muscle a actin (SMA; Figure 2D)
and fibroblast-specific protein marker S100A4 (FSP; Strutz
et al., 1995; Figure 2E). Cytokeratin (CK) 8 expression re-
mained confined to the luminal epithelial cells (Figure 2C), in-
dicating a true effect in the stroma and not an active epithelial
to mesenchymal transition (EMT; Figure 2; n = 9). For com-
parison, TgAPT121;p53+/+ prostates at 12 weeks of age
also show clear compartmental separation as verified by ep-
ithelial CK8 and mesenchymal SMA expression (Figures 2A
and 2B, respectively).
Morphologically, the prominent TgAPT121;p53
+/ tumors
could be classified as ‘‘phylloides-like’’ because of their re-
semblance to human breast and prostate phylloides tumors
(Shappell et al., 2004). However, unlike the usually benign
human tumors, these tumors reached massive size, growing
very rapidly (from 0.5 cm3 to > 2 cm3 over 4weeks), engulfing
many of the organs of the urogenital system and filling the
abdominal cavity. Given this difference, these tumors are
herein referred to as ‘‘stromal tumors,’’ although the epithe-
lium also comprises a significant abnormal component. Im-
portantly, similar stromal tumors were also observed in
44% of male TgAPT121;p53
+/+ mice, but only after 11
months of age (Figure 1J). Thus, development of such tu-
mors was facilitated by p53 heterozygosity but clearly re-
quired the APT121 transgene, since transgene negative
p53 heterozygous prostates were fully normal (not shown).
Furthermore, all TgAPT121;p53
/ mice developed similar
stromal tumors even more rapidly by 11 weeks of age (Fig-
ures 1H and 1L).c.
Figure 1. Histological Characterization and Temporal Progression of Prostate Tumorigenesis in TgAPT121 Prostates of Distinct
p53 Genotypes
Prostate morphologies in H&E-stained sections of 2-month-old mice are shown: (A) wild-type mice with a normally thin layer of epithelial (arrow) and stromal
cells (arrowhead), (B) TgAPT121;p53
+/+, (C) TgAPT121;p53
+/, and (D) TgAPT121;p53
/. The epithelial cells in TgAPT121;p53
/ prostates are pleiotropic
and grow in dense patterns. TgAPT121;p53
/ prostates contain an extensive hypercellular mesenchyme ([E], star). Stromal tumors develop in
TgAPT121;p53
+/ mice as young as 22 weeks of age (G) and consist of an abundance of stromal cells (star). These stromal tumors develop in
TgAPT121;p53
/ mice by 11 weeks (H). Stromal tumors ([F], arrows) in a 5-month-old TgAPT121;p53
+/ mouse prostate arose focally from the anterior
prostate (arrowhead). In these tumors T121 is expressed in epithelial cells ([I], arrow) but not in the stroma (star) as detected by immunofluorescence.
T121 is visualized as the merge (aqua) of green flourescein signal with blue DAPI counterstaining.
(J) By 8 weeks, TgAPT121 prostates broadly exhibit dysplasia, which is characterized by atypical cells with condensed chromatin, nuclear elongation, and
epithelial layer tufting. By 12 weeks, mPIN is extensive and regions of adenocarcinoma (Ad-ca) are often detected, characterized by further deterioration of
cellular morphology, disorganized growth patterns, and the presence of small back-to-back glands. Some mice develop stromal tumors (St/ep Tu) around
11 months.
(K) p53 heterozygosity increases the frequency and accelerates the onset of stromal tumors while mPIN and Ad-ca develop similarly to TgAPT121 mice.
(L) p53 nullizygosity accelerates the onset of mPIN, adenocarcinoma, and stromal tumors. TgAPT121;p53
/ mice also show the development of poorly
differentiated tumors (PD Ad-ca) at 22 weeks of age. Due to tumor-burden limitations, TgAPT121;p53
/ mice could not be aged beyond 24 weeks.
The number of animals analyzed in each group is indicated in parentheses.p53 Deficiency Results in Increased Mesenchymal
Cell Proliferation
Since the stroma was significantly expanded in TgAPT121;
p53/ prostates early in life with early onset of stromal tu-
mors and similar tumor development increased in frequency
and was accelerated in a p53+/ relative to p53+/+ back-
ground, we hypothesized that initiating tumorigenesis in
the epithelium by inactivation of pRb function had non-
cell-autonomously elicited a p53-mediated response in the
stromal fibroblasts resulting in the suppression of their prolif-
eration. Thus, reduction or loss of p53 in one or both com-
partments facilitated fibroblast proliferation and tumor devel-
opment. To test this hypothesis, we first examined the levels
of cell proliferation and p53 expression in epithelial and stro-
mal compartments prior to and after stromal tumor develop-
ment in each background. Using Ki67 immunofluoresenceCell 1(IF) to detect S phase cells, we confirmed that epithelial cells
in all cases showed similar high levels of proliferation as pre-
viously determined (Figure 3; Hill et al., 2005). At 2 months of
age, soon after transgene induction in prostate epithelium,
TgAPT121;p53
+/+ and TgAPT121;p53
+/ prostatic mesen-
chyme rarely contained Ki67-positive cells (Figures 3A, 3B,
and 3E). However, proliferating cells were readily detected
by this age within TgAPT121;p53
/ mesenchyme (Figures
3C and 3E). In all TgAPT121 backgrounds, once stromal tu-
mor masses were detectable, fibroblast proliferation was
widespread (Figure 3D), with Ki67-positive cells comprising
about 50% of that population (Figure 3E).
p53 Expression Loss in Stromal Tumor Fibroblasts
To further define the relationship between p53 and the
emergence of abnormal mesenchyme, we examined p5323, 1001–1011, December 16, 2005 ª2005 Elsevier Inc. 1003
expression by IF in prostates of all genotypes, early and after
progression. In nontransgenic prostates, p53 was undetect-
able in both epithelium and stroma (Figure 4A). However, in
the transgenic mice, where T121 was expressed specifically
in the epithelium, the epithelial cells anda subset ofmesenchy-
mal cells expressed p53 (n = 10; Figure 4B), consistent with an
inducedp53 response inbothcompartments. It is currently un-
clear what the relevant p53 response(s) is (are) in epithelium,
since neither apoptosis nor proliferation is affected by p53 de-
ficiency (Hill et al., 2005). However, in the mesenchyme, p53
induction appears to suppress fibroblast proliferation, since
these fibroblasts proliferate in a p53-deficient background
(compare Figures 3 and 4). This mechanism was confirmed
by the analysis of emerging stromal tumors in TgAPT121;
p53+/ prostates, where loss of p53 expression occurred spe-
cifically in the abundant stromal layers harboring proliferating
fibroblasts while being retained in the epithelium (n = 18; Fig-
ures 4C and 4D). Loss of fibroblast p53 expressionwas not re-
stricted to the p53 heterozygous background, as mesen-
chyme from histologically identical tumors arising in TgAPT121;
p53+/+ prostates had also undergone loss of p53 expression
(n = 8; Figure 4E).
Figure 2. Marker Characterization of Stromal Tumors
Prostate lesions in TgAPT121 mice at 12 weeks are comprised of aber-
rantly proliferating epithelial cells positive for cytokeratin 8 (brown, [A]) sur-
rounded by smooth muscle actin (SMA)-positive mesenchyme (brown,
[B]). The compartmental separation is retained within stromal tumors as
demonstrated by the identical marker-staining profile: (C) cytokeratin 8,
(D) SMA.
(A–D) Counterstained with hematoxylin. Expanding mesenchyme is also
positive for fibroblast-specific protein marker S100A4 (FSP) by IF (E). De-
tection of FSP was with flourescein (green) and nuclei were counter-
stained with DAPI (blue).1004 Cell 123, 1001–1011, December 16, 2005 ª2005 Elsevier InStromal p53 Mutation Selected during
Tumor Progression
To determine whether loss of p53 expression could have re-
sulted from the selection of fibroblasts that inactivated p53
by genetic mutation, stromal regions of TgAPT121;p53
+/ tu-
mors were isolated by laser capture microdissection (LCM)
and assayed by PCR for the presence of p53 wild-type
and null alleles (Figures 4F–4H). Strikingly, in four of six tu-
mors analyzed, proliferating stroma had selectively lost the
wild-type p53 allele (p < 0.0001 by Binomial exact test; Fig-
ure 4H), while nonproliferative stromal regions associated
with mPIN retained the wild-type p53 allele (Figure 4H,
control stroma). Moreover, when similar tumors arising in
TgAPT121;p53
+/+ prostates were analyzed for the number
of p53 gene copies present in the proliferative mesenchyme
by quantitative PCR analyses, most had undergone allele re-
duction (Table 1). Of 11 LCM-stromal samples from 11 inde-
pendent tumors, seven carried only a single p53 copy while
two had lost both copies. Two samples retained both p53
copies. Statistical analysis showed loss of a single or both
copies of p53 to be highly significant (p < 0.0001) by the Bi-
nomial exact test. These data support the hypothesis that
epithelial tumor initiation by cell cycle disruption places
a strong selective pressure on the mesenchyme for loss of
p53 function.
Notably, subsequent to p53 loss in the mesenchyme,
some epithelial regions also lost p53 expression (Figures
5A–5C), further supporting an as-yet-unknown p53 tumor
suppressor function in this compartment as well. Indeed,
these tumors are heterogeneous, and many distinct neo-
plastic cell populations often coexist in the same gland.
Epithelial cells that had lost p53 expression weremorpholog-
ically similar to those of TgAPT121;p53
/ prostate epithe-
lium (Figure 1D) and produced lesions that were disorga-
nized and pleiotropic compared to adjacent p53-positive
epithelium (Figure 5A).
DISCUSSION
Our knowledge of genetic and epigenetic changes affecting
cancer progression derives largely from analyses of events
within the ‘‘cancer cell’’ itself. Indeed, animal-model studies
show that cancer initiation and progression can be modeled
by engineering specific lesions targeted to the presumed cell
of origin (reviewed in Van Dyke and Jacks [2002]). However,
sporadic human cancers evolve to harbor selective changes
as a result of pressures imposed within a complex microen-
vironment. Each aberrant change can impact both the biol-
ogy of the tumor cell and its surroundings (Hanahan and
Weinberg, 2000), creating new selective pressures that likely
affect the natural course of cancer evolution. Thus, full un-
derstanding requires experimental assessment of these evo-
lutionary dynamics that ultimately produce a tumor with all
the properties of a ‘‘neoplastic organ.’’
Recent reports have suggested the presence of tumor-
suppressor mutations in the stroma of some human epi-
thelial cancers (carcinomas), indicating that the selection of
aberrant cells within the microenvironment occurs, likelyc.
Figure 3. Proliferation Assessment in Subcompartments of Developing Tumors
Prostate samples were assessed for the expression of the S phase marker Ki67 via immunofluorescence in (A)–(D) (signal appears yellow as a merge of
flourescein with red DAPI nuclear stain). The percentage of stromal cells positive for Ki67 were quantified in (E). Prostates of 2-month-old
TgAPT121;p53
+/+ (A), TgAPT121;p53
+/ (B), and TgAPT121;p53
/mice (C) prior to tumor development show extensive proliferation in all epithelial compart-
ments (arrows), while stromal (arrowheads) proliferation is only apparent in the hypercellular mesenchyme (star) of TgAPT121;p53
/ prostate (C and E). A
significant increase in the proliferation index within the stroma occurs in tumors (E). A representative tumor with extensive stroma (star) from a 5-month-old
TgAPT121;p53
+/mouse is shown in (D). In (E), the proliferation index is measured as the percentage of cells in S phase, calculated by counting Ki67-positive
cells (yellow) as a percentage of total cells (DAPI red) of a given compartment based onmorphology. Four random fields were examined for each tissue. Each
data set was derived from analysis of 3 mice, and is expressed as mean ± SEM.influencing cancer progression overall (Fukino et al., 2004;
Kurose et al., 2001; Matsumoto et al., 2003; Moinfar et al.,
2000; Paterson et al., 2003; Tuhkanen et al., 2004; Wernert
et al., 2001). However, given the limitations of studying indi-
vidual human samples and the inability to experimentally
determine the role of putative microenvironment mutations
during tumor progression, such reports have met with sub-
stantial skepticism. Here, through studies in mice genetically
engineered to initiate prostate carcinoma (Hill et al., 2005),
we show that cancer evolution can indeed involve the selec-
tion of genetic changes in the microenvironment as a result
of nonautonomous pressures imposed by oncogenic stress
within the epithelium.
Oncogenic Stress in Prostate Epithelium and a
Tumor-Suppression Response in the Mesenchyme
To gain more insight into the role of p53 in prostate tumor
suppression, we analyzed the development of prostate le-
sions in TgAPT121mice of p53 heterozygous and nullizygous
backgrounds. In TgAPT121 mice, pRb function is absent in
prostate epithelial cells due to cell-specific expression of
T121, a fragment of SV40 T antigen that binds and inactivates
pRb, p107, and p130. As a result, the epithelial cells pro-
liferate aberrantly triggering a cell-autonomous tumor-
suppression response, the p53-independent induction of
Pten-mediated apoptosis (Hill et al., 2005). The current
genetic analysis of p53 function in this system led to the sur-
prising discovery that this epithelial oncogenic stress also
nonautonomously induces a p53 response in the associatedCell 1prostate mesenchyme. In nontransgenic prostates, p53 is
undetectable in both epithelium and stroma. However, in re-
sponse to the inactivation of pRb function in the epithelium,
p53 expression is induced in both the epithelial cells and
in stromal fibroblasts consistent with a p53-dependent
tumor-suppression response in both compartments. What
the relevant response(s) is in epithelium is currently un-
known, since neither apoptosis nor proliferation are quantita-
tively affected by p53 deficiency (Hill et al., 2005). However,
in stromal fibroblasts, we show here that p53 plays a critical
role in suppressing cell proliferation. When T121 is expressed
in the prostate epithelium of p53 null mice, associated
stromal fibroblasts proliferate, resulting in an extensive
hypercellular mesenchyme within 2 weeks of transgene
induction.
Such an effect is not the result of p53 deficiency in the ep-
ithelium. In TgAPT121;p53
+/mice, loss of p53 expression in
the mesenchyme during tumor progression is associated
with fibroblast proliferation, while p53 expression is intact
in the epithelium. Quantitative analysis of fibroblast prolifera-
tion shows proliferation in this compartment occurs only
upon p53 inactivation and only in the presence of epithelial
T121 expression. The fact that the proliferation rate of p53
null stromal fibroblasts soon after transgene induction is
lower than that in tumors postselection suggests that only
a subset of fibroblasts are initially responsive to the epithelial
signal and then subsequently expand to constitute the major
mesenchymal component of tumors. Thus, the data are
consistent with a model in which oncogenic stress in the23, 1001–1011, December 16, 2005 ª2005 Elsevier Inc. 1005
Figure 4. p53 Induction and Loss in TgAPT121;p53
+/ Tumors
p53 expression was detected by IF (flourescein; yellowmergewith DAPI red) in (A), (B), (D), and (E). At 2 months of age, p53 is undetectable in nontransgenic
prostates (A) but significantly induced in both epithelial cells and stromal fibroblasts of TgAPT121 prostates (B). Serial sections of an emerging stromal tumor
(arrowhead) with expanding mesenchyme (star) and adjacent mPIN (arrow) are shown in ([C]; H&E) and ([D]; p53 IF). p53 expression is lost in the tumor
mesenchyme (star) and retained in the epithelium in addition to the mPIN-associated stroma (arrow). A total of 18 TgAPT121;+/p53
+/ mice with stromal
tumors were examined, and all were found to have lost p53 expression in the stroma. Similar stromal loss of p53 expression is observed in stromal tumors
arising in TgAPT121;p53
+/+ mice (n = 8). A representative tumor from a 72-week-old mouse is shown in (E). An H&E-stained prostate section from
a TgAPT121;p53
+/ mouse is shown before (F) and after (G) laser-capture microdissection (arrow indicates the stromal region from which cells were iso-
lated).
(H) PCR amplification specific for wild-type or null p53 alleles was performed on laser-captured samples from TgAPT121;p53
+/ mice, including control
stroma (associated with dysplasia/PIN histology; e.g., [D], arrow) and stroma from six independent tumors. TgAPT121;p53
+/ tail DNA served as a positive
control. Binomial exact test showed loss of the wild-type p53 allele in tumor stroma of TgAPT121;p53
+/ mice was statistically significant (p < 0.0001).epithelium provides a mitogenic signal to the mesenchyme,
thus inducing a p53 response. p53 activation suppresses
stromal fibroblast proliferation, constituting a selective pres-
sure against p53 in that compartment (Figure 6).
Selective Evolution of the Mesenchyme Associated
with Initiated Epithelium
To determine whether the highly proliferative stromal mesen-
chyme of tumors could have resulted from the selective ex-
pansion of fibroblasts that had undergone genetic inactiva-
tion of p53, stromal and epithelial regions of tumors were
isolated by laser capture microdissection and assayed by
PCR for the presence of p53 wild-type and null alleles. Strik-
ingly, proliferating stroma within the majority of tumors had
indeed lost the wild-type p53 allele, while nonproliferative
stromal regions retained the wild-type p53 allele. Impor-
tantly, similar mesenchymal p53 loss occurred in ‘‘sporadic’’
stromal tumors arising at older ages in TgAPT121;p53
+/+1006 Cell 123, 1001–1011, December 16, 2005 ª2005 Elsevier Inmice. The multicompartment evolution during TgAPT121
prostate tumor progression (Figure 6) indicates the likelihood
that similar mechanisms are active during human tumorigen-
esis and may explain the stromal mutations previously
observed in sporadic epithelial cancers.
For several reasons, it is unlikely that the stromal growth
observed in these studies represents an EMT occurring after
p53 loss. EMT is hypothesized to facilitate malignant tumor
progression by causing the transdifferentiation of epithelial
cells into a fibroblast-like phenotype (Thiery, 2002). How-
ever, from the earliest induction of T121 expression in the ep-
ithelium, p53 expression is induced in both the epithelial and
mesenchymal compartments, while the boundaries be-
tween epithelial and stromal compartments are clearly pre-
served. Furthermore, germline inactivation of p53 together
with T121 epithelial expression causes detectable prolifera-
tion of a subset of stromal fibroblasts. In all stages analyzed,
including terminal tumors, there is no evidence of epithelialc.
and fibroblast marker coexpression frequently observed
in tumor-associated EMT (Saika et al., 2004). Additionally,
the proliferative mesenchyme that develops in p53 heterozy-
gous, null, and wild-type backgrounds does not represent
the selection of a normal p53 negative subpopulation but
rather a selection for cells that have inactivated p53 by ge-
netic loss. In contrast, loss of epithelial p53 expression is
focally detectable significantly later (Figure 5).
Roles for Mutant Mesenchyme in Potentiating
Epithelial Cancer
Analysis of the stromal tumors in TgAPT121;p53
+/ prostates
showed that loss of p53 expression occurred specifically in
the stromal compartment while being retained in the epithe-
lium. Interestingly, at later times, some regions of epithelium
Table 1. Loss of Wild-Type p53 Alleles in Stromal
Tumors of TgAPT121Mice
Tissue Genotype 2DDCt
Number of
Wild-Type
p53 Alleles
Muscle p53+/+ 1.473 2
Muscle p53+/+ 0.679 2
Muscle p53+/ 0.524 1
Muscle p53+/ 0.593 1
Muscle p53/ 0.112 0
Stromal tumor 1 APT121;p53
+/+ 0.317 1
Stromal tumor 2 APT121;p53
+/+ 0.567 1
Stromal tumor 3 APT121;p53
+/+ 0.377 1
Stromal tumor 4 APT121;p53
+/+ 0.579 1
Stromal tumor 5 APT121;p53
+/+ 0.670 2
Stromal tumor 6 APT121;p53
+/+ 0.398 1
Stromal tumor 7 APT121;p53
+/+ 1.051 2
Stromal tumor 8 APT121;p53
+/+ 0.035 0
Stromal tumor 9 APT121;p53
+/+ 0.285 1
Stromal tumor 10 APT121;p53
+/+ 0.046 0
Stromal tumor 11 APT121;p53
+/+ 0.534 1
Real-time quantitative PCR was performed on DNA extracted
from LCM samples to determine the status of wild-type p53 al-
leles in stromal tumors or tissues of TgAPT121mice. LCMmuscle
samples were used as controls. Among 11 stromal tumor sam-
ples from 11 distinct animals, seven showed loss of one wild-
type allele of p53, two showed loss of both alleles of p53, while
two retained both wild-type alleles. DDCt = (sample Ct[p53] 
sample Ct[b-actin])  (p53+/+ control Ct[p53]  p53+/+ control
Ct[b-actin]). Ct = the number of cycles required to reach a thresh-
old value which is set within the exponential phase of the loga-
rithmic scale amplification plot. Analysis of standard samples in-
dicate that copy numbers of 2, 1, and 0 are indicated by 2DDCt
values of >0.6, between 0.15 to 0.6, and <0.15, respectively.
Loss of a single and both copies of wild-type p53was statistically
significant by Binomial exact test (p < 0.0001) assuming a ran-
dom probability of 1%.Cellalso lost p53 expression (Figure 5). Importantly, epithelial
p53 loss was detectable only subsequent to mesenchymal
p53 loss and expansion. This observation raises the possi-
bility that p53-deficient stromal cells nonautonomously in-
crease the selective pressure against p53 function in the
epithelium. Epithelial regions with p53 loss were morpholog-
ically distinct from adjacent p53-expressing regions, includ-
ing increased disorganization and nuclear atypia, as was ap-
parent in p53 null TgAPT121 epithelium. Though currently
correlative, this result suggests that a p53-deficient mesen-
chyme may also promote epithelial cell tumorigenesis by fur-
ther altering the balance of selective pressures. In support of
this hypothesis, a recent study showed that the tumorigenic-
ity of MCF7 human breast cancer cells in SCID mice differed
based on the host’s p53 status. Tumor onset occurred with
reduced latency in p53-deficient recipients, indicating that
p53-deficient stroma does indeed have the potential to ac-
celerate epithelial tumorigenesis (Kiaris et al., 2005). Further-
more, the tumor stroma in p53 heterozygous hosts showed
p53 LOH indicating the selection of p53-deficient fibroblasts
is required (Kiaris et al., 2005). In our current studies, such
changes occur during spontaneous tumor development
subsequent to epithelial initiation.
Experimental tissue recombination studies in which epi-
thelial and mesenchymal cells are isolated from normal or
tumor samples, in some cases from distinct genotypes
have demonstrated that the stromal compartment can effect
neoplastic change within associated ‘‘normal’’ epithelium
(Cunha et al., 2003). Recently, somatic interference with
fibroblast TGF-b responsiveness via Cre-mediated inactiva-
tion of its receptor TBRII was shown to induce invasive squa-
mous cell carcinoma of the forestomach and PIN in the pros-
tate along with an increased abundance of stromal cells in
these tissues (Bhowmick et al., 2004a). Thus, it is possible
that selective changes in the stroma can lead to further
selection of the epithelium. Whether such a mechanism ex-
plains the eventual loss of p53 and progression of the epithe-
lium in TgAPT121 prostate tumors is addressable by similar
compartment-specific mutation or tissue-recombination
approaches.
Implications for Human Cancers
Whether the model described here for p53 roles in mouse
prostate tumorigenesis are directly relevant to mechanisms
of human prostate cancer or can only be interpreted to re-
flect the possibility for multicompartment evolution in some
epithelial tissues is not yet clear. In the TgAPT121 model,
p53 loss in fibroblasts associated with initiated epithelium re-
sults in the aggressive expansion of the mesenchyme, which
ultimately comprises the bulk of the tumor, although slower-
growing adenocarcinomas are clearly present. Whether the
stromal overgrowth relative to carcinoma reflects mouse/
human differences or is a property of the prostate remains
to be determined. In the TgAPT121 model, the spontaneous
evolution of prostate epithelial tumor cells is extremely slow,
progressing only to microinvasive adenocarcinoma (Hill
et al., 2005). We previously showed that carcinoma progres-
sion is accelerated in a Pten heterozygous background, and
progression of the carcinoma occurs spontaneously with123, 1001–1011, December 16, 2005 ª2005 Elsevier Inc. 1007
Figure 5. Epithelial p53 Loss Subsequent to Stromal p53 Loss Compounds Heterogeneous Tumor Progression
In H&E-stained TgAPT121;p53
+/ tumor sections (A), regions of dense epithelial cell growth morphologically distinct from surrounding epithelium (arrows)
grow in small back-to-back circular glands (arrowheads). IF for p53 (yellow) shows that such regions no longer express p53 (B and C). Representative tu-
mors from 7- (B) and 9 (C)-month-old TgAPT121;p53
+/mice are shown. The blue bar indicates the relative timing of p53 expression and loss based on p53
IF analysis of prostates from TgAPT121;p53
+/ mice (n = 28). Focal epithelial loss occurred subsequent to p53 loss in the stroma.Pten inactivation to invasive carcinoma (Hill et al., 2005). This
result is consistent with the high incidence of Pten inactiva-
tion in advanced human prostate cancer (Feilotter et al.,
1998; Ittmann, 1996). However, in a Pten wild-type back-
ground, such as in the present study, spontaneous Pten
loss and carcinoma progression has not been observed,
possibly reflecting a species-specific constraint on allele
loss. The resistance to spontaneous epithelial Pten
inactivation may explain dominance of the proliferative mes-
enchyme upon selective p53 loss. It is interesting that Li-
Fraumeni patients have a low incidence of prostate cancer
(Kleihues et al., 1997), although they do display a higher-
than-normal incidence of phylloides cancers (Birch et al.,
2001). Also, rare human malignant phylloides cancers in
the prostate and breast lack p53 expression in both epithelial1008 Cell 123, 1001–1011, December 16, 2005 ª2005 Elsevier Inand stromal cell components (McCarthy et al., 2004) or ex-
press mutant p53 (Gatalica et al., 2001).
The present studies do provide evidence that coevolution
of the stromal compartment, with selection of genetically al-
tered cells, can occur as a result of oncogenic stress in the
epithelium. Such mechanisms may explain the observation
of stromal tumor-suppressor mutations, including in p53
(Kurose et al., 2002; Paterson et al., 2003) and in Pten
(Kurose et al., 2002), in human carcinomas, including breast
(Fukino et al., 2004; Kurose et al., 2001; Moinfar et al., 2000;
Wernert et al., 2001), colon (Matsumoto et al., 2003;Wernert
et al., 2001), and ovary (Tuhkanen et al., 2004). Our work
represents the first in vivo model of spontaneous tumor
progression to identify selective mutation in reactive stroma
as a mechanism for neoplastic acceleration, suggestingFigure 6. A Model for Multicompartment Tumor Evolution Triggered by Epithelial Cell Disruption
Normal epithelial-mesenchymal interactions are perturbed by cell cycle disruption (depicted as a mitotic figure) in the epithelium upon inactivation of pRb,
p107, and p130 (dashed black border). As a result, p53 is induced in both epithelial cells and stromal fibroblasts (red nuclei). Non-cell-autonomous signals
from initiated epithelium induce a p53 growth-suppression response in stromal fibroblasts (yellow arrow), which creates selective pressure against p53 func-
tion. Once p53 is inactivated (navy nuclei), stromal fibroblasts proliferate in continued response to the aberrant epithelium. p53 expression is subsequently
lost in some epithelial cells, either stochastically or by generation of new selective pressures conferred by aberrant stroma (orange arrow). This model is
consistent with the full body of data presented herein.c.
that stromal mutation in epithelial cancer can play a signifi-
cant role in overall cancer development. These studies un-
derscore the dynamic complexity of cell-cell interactions
and the changing selective microenvironment that drives
cancer development. Whether cells in the microenvironment
in addition to fibroblasts are susceptible to selective genetic
change remains to be determined. However, the present
results encourage further exploration of this possibility and
emphasize both the need to determine the cell of origin for
mutations detected in human cancers and the potential im-
portance for developing cancer therapies that target the
stromal compartment as a means to prevent acceleration
or possibly even suppress tumorigenesis.
EXPERIMENTAL PROCEDURES
Breeding Strategies
Derivation of TgAPT121 transgenic mice was previously described (Hill
et al., 2005). TgAPT121 mice were identified by PCR amplification of a
160 bp T121 fragment using primers 5
0-GAATCTTTGCAGCTAATGGA
CC-30 and 50-GCATCCCAGAAGCTCCAAAG-30 and digit-derived geno-
mic DNA as template. The cycling profile was as follows: 94ºC, 2 min; 35
cycles of 94ºC, 20 s; 62ºC, 45 s; 72ºC, 45 s; and final incubation at 72ºC,
2 min. TgAPT121 mice were maintained by crossing to nontransgenic
B6D2F1 mice and therefore are designated as B6; D2-TgAPT121 (Tvd
TgAPT121). To study the effect of p53 inactivation on prostate tumorigen-
esis, TgAPT121 mice were mated to p53 nullizygous mice (p53tm1Tyj;
Jackson Laboratory). p53 genotypes were determined by PCR using
two reactions (Lowe et al., 1993): one amplifies the neomycin insertion
site (neomycin primer, 50-TCCTCGTGCTTTACGGTATC-30; p53 primer,
50-TATACTCAGAGCCGGCCT-30; 525 bp product) and the other ampli-
fies the endogenous p53 allele (substituting 50-ACAGCGTGGTGGTAC
CTTAT-30 for the neomycin primer, 475 bp product). Cycling parameters
were the same as for the T121 reaction described above. We used stan-
dard breeding strategies to produce TgAPT121;p53
+/+, TgAPT121;
p53+/, and TgAPT121;p53
/ mice, and nontransgenic male littermates
(p53+/+, p53+/, or p53/) served as controls.
Histopathology
Prostate and tumor samples were dissected from male mice, and a por-
tion was fixed overnight in 10% phosphate-buffered formalin, transferred
to 70%ethanol, then embedded in paraffin. To analyze tumormorphology
and development, prostate samples were sectioned for 10 successive
layers at 5 mm intervals and stained with hematoxylin and eosin (H&E)
for histopathological examination as previously described (Hill et al.,
2005).
Immunodetection
Immunohistochemical analysis was performed on formalin-fixed paraffin
sections. Antigen retrieval for all antibodies was by boiling in citrate buffer
(pH 6.0; Zymed, South San Francisco, CA) for 15 min. Endogenous per-
oxidase activity was quenched with a 10 min incubation in 3% H2O2 in
methanol. Antibodies used were anti-cytokeratin 8 (1:100, sheep poly-
clonal, PH182, Binding Site, Birmingham, UK), anti-smooth muscle actin
(1:1000, mouse A2537, Sigma, St. Louis, MO), anti-p53 (1:500, rabbit
polyclonal CM5, Novocastra, Newcastle upon Tyne, NE12 8EW, UK),
anti-SV40 T antigen (N-terminal-specific monoclonal Ab2, 1:100, Onco-
gene, Cambridge, MA), anti-Ki67 (1:2000, goat polyclonal M-19, Santa
Cruz Biotechnology, Santa Cruz, CA), and anti-FSP (S100A4) (1:500,
mouse 1B10, Sigma, St. Louis, MO). Detection for all antibodies was per-
formed using the Vector ABC Elite Kit and a Vector DAB kit for substrate
detection (Vector Labs, Burlingame, CA). Immunofluorescence followed
the same protocols except that signal amplification used the TSA Plus
Fluorescence System (Perkin Elmer, Wellesley, MA). Slides were counter-Cellstained with DAPI and mounted using Vector Hardset Mounting Media
(Vector Labs, Burlingame, CA).
Laser-Capture Microdissection and LOH Analysis
Laser-capture microdissection (LCM) of H&E-stained sections was per-
formed using a Leica AS LMDwith a pulsed 337 nmUV laser (LeicaMicro-
systems Inc., Bannockburn, IL). Formalin-fixed paraffin-embedded tissue
sections were mounted onto Glass Foiled PEN slides (Vashaw Scientific,
Atlanta, GA). Cells were collected in a cap of the tube containing 50 ml of
lysis buffer (10 mM Tris-HCl [pH 8.0], 1% Tween 20). Following specimen
collection, the samples were spun for 15 s and then 5 ml of proteinase K
(100 mg/ml) was added to the samples, which were incubated at 55ºC
overnight. Proteinase K was inactivated at 99ºC for 10 min, and 5–10 ml
aliquots were used for PCR analysis. The primers for semiquantitative
PCR were as follows: wild-type p53 (173 bp) forward 50-CATCACCTCAC
TGCATGGAC-30, reverse 50-AAAAGATGACAGGGGCCATG-30; Neo
(p53 null; 160 bp) forward 50-ATGATTGAACAAGATGGATTGC-30, re-
verse 50-ACAGGTCGGTCTTGACAAAA-30. The PCR condition was
94ºC 10 min, 35 cycles of 94ºC 30 s, 58ºC 90 s, and 72ºC 45 s, and
72ºC 10 min. Products were resolved in 2% agarose gels and visualized
under UV light. Quantitative real-time PCR analysis was performed on
LCM TgAPT121;p53
+/+ stromal tumors and tissue samples to determine
the status of wild-type p53 alleles. Primers were as follows: p53 forward
(FAM labeled) 50-caacagaCTCACTGCATGGACGATCTGtTG-30, reverse
50-GGCTTCACTTGGGCCTTCAA-30; b-actin forward 50-GGTGGGAATG
GGTCAGAAGG-30, reverse (Joe labeled) 50-caactgTCTCCATGTCGTCC
CAGtTG-30 (Invitrogen Life Technologies, Carlsbad, CA). Each 12 ml reac-
tion mixture contained 5 ml of LCM DNA template, 200 nM p53 primers,
200 nM b-actin primers, 200 nM deoxynucleoside triphosphates, 1.2 ml
of 10 buffer, and 0.3 U Taq DNA polymerase (Boehringer Mannheim,
Germany). Cycling was as follows: 94ºC 2 min, 40 cycles of 94ºC 15 s,
58ºC 30 s, and 72ºC 60 s. The reaction was performed in 384-well clear
optical reaction plate (Applied Biosystems, Foster City, CA) using
ABI7700 Sequence Detection System (Applied Biosystems, Foster City,
CA), and the data were analyzed using SDS 2.1 software (Applied Bio-
systems, Foster City, CA) and standard protocols (http://www.applied
biosystems.com). The copy number of each sample was determined by
calculating DDCt based on the formula DDCt = (sample Ct[p53] sample
Ct[b-actin])  (p53+/+ control Ct[p53]  p53+/+ control Ct[b-actin]), where
Ct is the number of cycles required to reach a threshold based on linear
amplification. The p53+/+ control Ct for p53 and b-actin was the average
Ct of the two p53
+/+muscle samples. Analyses of standard samples indi-
cate copy numbers of 2, 1, and 0 by 2DDCt values of >0.6, 0.15 to 0.6,
and <0.15, respectively.
Statistical Analysis
A Binomial exact test was performed using SAS 9.1 (Cary, NC) to deter-
mine whether loss of the wild-type p53 allele was statistically significant in
tumor stroma of TgAPT121;p53
+/ and TgAPT121;p53
+/+ mice. The prob-
ability of random wild-type p53 allele loss in the tumor stroma was arbi-
trarily set at 1%. However, results remain significant (p < 0.0001) even if
the probability of random loss is as high as 10%.
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